The FeNO measuring device market continues to attract growing attention from healthcare technology researchers, respiratory specialists and medical equipment suppliers.
Two market research reports published in 2026 forecast significant expansion in devices that are used to measure fractional exhaled nitric oxide (FeNO); a biomarker associated with type 2 airway inflammation and asthma management.
Although the reports differ considerably in their market valuations, both reports clearly anticipate sustained growth over the coming decade.
So for hospitals, respiratory clinics and healthcare procurement teams, the interesting question may not be how large the market eventually becomes, but what these projections suggest about the future availability and adoption of FeNO testing technology.
FeNO Measuring Device Market Size and Growth Forecasts
Two recent industry reports provide different perspectives on the global FeNO device market.
- Market Research Future (MRFR), in a report updated in August 2026, estimates that the market was worth approximately US$567.7 million in 2024, forecasting growth to US$1.208 billion by 2035.
- Meanwhile, a July 2026 report by OG Analysis, distributed through Research and Markets, estimates a smaller market of US$141.1 million in 2026, growing to US$340.9 million by 2034.
Comparing the FeNO Market Forecasts
| Market indicator | Market Research Future | Research and Markets / OG Analysis |
|---|---|---|
| Base market valuation | $567.7 million (2024) | $141.1 million (2026) |
| Forecast valuation | $1.208 billion (2035) | $340.9 million (2034) |
| Forecast Compound Anuual Growth rate (CAGR) | 7.11% | 12.2% |
| Report publication/update | August 2026 | July 2026 |
***Figures are publisher estimates and forecasts, not independently audited industry revenue. The reports use different base years and forecast periods.
Despite the substantial differences in valuation, the reports both share an important conclusion: both anticipate a market that will more than double over their respective forecast periods.
That suggests considerable confidence in the longer-term commercial potential of FeNO measurement technology.
However, the difference in estimates also highlights the uncertainty involved in measuring a relatively specialised medical device market.
Which Regions Dominate the FeNO Measuring Device Market?
Market Research Future provides an approximate geographical breakdown of the industry.
| Region | Approximate share |
|---|---|
| North America | 45% |
| Europe | 30% |
| Asia-Pacific | 20% |
| Middle East and Africa | 5% |
These figures indicate that North America and Europe account for the majority of the market covered by MRFR’s regional estimates.
The report also identifies Asia-Pacific as a particularly promising growth region, citing increasing respiratory healthcare needs and investment in diagnostic technologies.
What Does This Mean for Africa?
The Middle East and Africa’s relatively small estimated share may indicate that FeNO technology has not yet achieved the same level of market penetration as in more established healthcare markets.
- However, a smaller market share should not automatically be interpreted as unmet demand or an immediate commercial opportunity.
Adoption depends on several factors that include:
- healthcare financing,
- access to specialist respiratory services,
- equipment affordability,
- consumable supply and clinical training.
So for hospitals and private respiratory clinics that are evaluating new diagnostic capabilities, the opportunity lies in determining whether FeNO testing can address a genuine clinical need within their existing services.
Asthma Monitoring Remains the Leading Application
According to Market Research Future, asthma monitoring represents the largest application segment of the FeNO measuring device market.
- The report estimates its 2024 value at approximately US$227.1 million, representing around 40% of its overall market estimate.
This finding is consistent with FeNO’s established clinical relevance.
FeNO measurements provide information about type 2 airway inflammation and can help clinicians assess the likelihood of corticosteroid responsiveness.
The BTS/NICE/SIGN asthma guideline includes FeNO testing within defined asthma diagnostic pathways.
For respiratory specialists, this provides an important distinction between FeNO devices and conventional lung function equipment.
- Spirometry assesses airflow and lung function, whereas FeNO testing provides information about inflammatory activity. The two measurements can complement one another when clinically indicated.
- MRFR also identifies chronic obstructive pulmonary disease (COPD) management as a potentially fast-growing application segment.
Nevertheless, FeNO’s clinical role in COPD is less established than its role in asthma. Market projections should not be interpreted as evidence that FeNO testing is routinely recommended for all COPD patients.
Portable FeNO Devices and Home Monitoring: An Emerging Opportunity?
As mentioned earlier, a notable finding in the MRFR report related to portable equipment.
- The research estimates that portable FeNO measuring devices represented approximately US$227.1 million of the market in 2024.
That suggests that portable devices accounted for roughly 40% of the publisher’s estimated market value.
We believe that the significance of this trend extends beyond more than just convenience.
- Portable technologies such as Bosch Vivatmo can potentially support FeNO measurements in outpatient clinics, smaller medical practices and other suitable healthcare environments without requiring extensive laboratory infrastructure.
Home monitoring represents such a related development.
Instead of relying exclusively on measurements taken during clinical appointments, suitable patients may be able to record FeNO values between visits, with healthcare professionals reviewing trends as part of ongoing asthma management.
However, greater access to measurement does not eliminate the need for clinical interpretation.
FeNO values can be influenced by medication, allergic conditions, smoking and other factors. Home measurements should therefore support, rather than replace, appropriate medical supervision.
Where Does Bosch Vivatmo Fit Into This Market?
The expanding interest in professional and portable FeNO measurement is relevant to technologies such as Bosch Vivatmo.
Bosch Healthcare Solutions has developed FeNO measurement solutions for different settings, including:
- Vivatmo PRO for professional labs, hospitals and clinics, as well as
- Vivatmo ME for personal asthma monitoring.
- Vivatmo Me also incorporates digital monitoring through the Vivatmo app, which allows users to track readings over time and discuss them with healthcare professionals.
These technologies illustrate how manufacturers are addressing two distinct needs:
- clinical FeNO assessment and
- selected home-monitoring applications.
The Research and Markets report specifically includes Bosch Healthcare Solutions and Vivatmo among the companies and products covered in its competitive landscape.
This establishes Bosch’s relevance to the industry being analysed, although the publicly available report does not provide sufficient evidence to determine Bosch’s individual market share.
Further product information is available from the official Bosch Vivatmo website.
Interested in FeNO Measuring Equipment for Your Healthcare Facility?
For respiratory specialists, hospitals and healthcare organisations that are considering FeNO testing, selecting the suitable technology requires an understanding of clinical applications, operating requirements and long-term costs.
At MediDiagAfrica, we explore diagnostic technologies that may help healthcare providers strengthen their services, including Bosch Vivatmo FeNO measurement solutions.
- Are you considering Vivatmo pro for your respiratory clinic or exploring FeNO monitoring technology?
We welcome enquiries from healthcare professionals, hospital administrators and medical equipment procurement teams seeking to evaluate appropriate respiratory diagnostic technologies.
Market figures are forecasts published by independent research providers. They should not be interpreted as guaranteed future revenues or evidence of local demand. Product availability and regulatory status vary by country.